CRA Financial Services’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,355
| Closed | -$235K | – | 324 |
|
|
2026
Q1 | $235K | Buy |
8,355
+228
| +3% | +$6.07K | 0.03% | 267 |
|
|
2025
Q4 | $202K | Sell |
8,127
-877
| -10% | -$22.1K | 0.03% | 286 |
|
|
2025
Q3 | $229K | Sell |
9,004
-809
| -8% | -$20K | 0.03% | 274 |
|
|
2025
Q2 | $238K | Sell |
9,813
-615
| -6% | -$14.3K | 0.04% | 247 |
|
|
2025
Q1 | $264K | Sell |
10,428
-483
| -4% | -$12.6K | 0.05% | 221 |
|
|
2024
Q4 | $289K | Sell |
10,911
-5,908
| -35% | -$160K | 0.05% | 204 |
|
|
2024
Q3 | $487K | Sell |
16,819
-616
| -4% | -$18K | 0.09% | 141 |
|
|
2024
Q2 | $488K | Sell |
17,435
-1,715
| -9% | -$47.2K | 0.1% | 134 |
|
|
2024
Q1 | $531K | Buy |
19,150
+1,105
| +6% | +$30.7K | 0.12% | 122 |
|
|
2023
Q4 | $520K | Sell |
18,045
-755
| -4% | -$22.8K | 0.13% | 115 |
|
|
2023
Q3 | $624K | Sell |
18,800
-69
| -0.4% | -$2.44K | 0.17% | 96 |
|
|
2023
Q2 | $692K | Sell |
18,869
-2,816
| -13% | -$110K | 0.19% | 91 |
|
|
2023
Q1 | $885K | Sell |
21,685
-2,448
| -10% | -$106K | 0.26% | 71 |
|
|
2022
Q4 | $1.24M | Sell |
24,133
-350
| -1% | -$16.8K | 0.4% | 54 |
|
|
2022
Q3 | $1.07M | Buy |
24,483
+1
| +0% | +$49 | 0.39% | 53 |
|
|
2022
Q2 | $1.28M | Buy |
24,482
+252
| +1% | +$12.8K | 0.44% | 46 |
|
|
2022
Q1 | $1.25M | Buy |
24,230
+868
| +4% | +$45K | 0.38% | 48 |
|
|
2021
Q4 | $1.38M | Buy |
23,362
+60
| +0.3% | +$2.97K | 0.41% | 43 |
|
|
2021
Q3 | $1M | Buy |
23,302
+2,009
| +9% | +$89K | 0.34% | 54 |
|
|
2021
Q2 | $834K | Sell |
21,293
-1
| -0% | -$39 | 0.29% | 70 |
|
|
2021
Q1 | $771K | Sell |
21,294
-503
| -2% | -$17.9K | 0.3% | 72 |
|
|
2020
Q4 | $802K | Buy |
21,797
+1,564
| +8% | +$57.4K | 0.34% | 59 |
|
|
2020
Q3 | $704K | Buy |
20,233
+5,925
| +41% | +$208K | 0.34% | 64 |
|
|
2020
Q2 | $444K | Buy |
14,308
+1,983
| +16% | +$67.4K | 0.23% | 87 |
|
|
2020
Q1 | $382K | Buy |
12,325
+2,494
| +25% | +$85K | 0.24% | 87 |
|
|
2019
Q4 | $365K | Buy |
9,831
+1,220
| +14% | +$43.5K | 0.2% | 98 |
|
|
2019
Q3 | $294K | Sell |
8,611
-1,030
| -11% | -$37.5K | 0.18% | 104 |
|
|
2019
Q2 | $396K | Buy |
9,641
+644
| +7% | +$25.6K | 0.24% | 89 |
|
|
2019
Q1 | $363K | Sell |
8,997
-1,975
| -18% | -$79.1K | 0.24% | 94 |
|
|
2018
Q4 | $455K | Buy |
+10,972
| New | +$455K | 0.33% | 76 |
|
Other funds holding PFE
CRA Financial Services's PFE Position: Q2 2026 in Review
CRA Financial Services sold out of Pfizer (PFE) in Q2 2026, closing a stake of 8,355 shares — an estimated $235K sold.
CRA Financial Services first reported a position in PFE in Q4 2018 and held it in 30 quarters. The position peaked at $1.38M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- CRA Financial Services reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- CRA Financial Services sold 8,355 Pfizer shares in Q2 2026, an estimated $235K.
- CRA Financial Services first reported a position in Pfizer in Q4 2018 and held it in 30 quarters.
- CRA Financial Services's Pfizer position peaked at $1.38M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on CRA Financial Services's 13F filing for Q2 2026, filed 24 Jul 2026.